Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of cardiovascular diseases
3.2.1.2 Growing awareness of health benefits
3.2.1.3 Advancements in research and development
3.2.1.4 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs associated with omega-3 drugs
3.2.2.2 Potential side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Vascepa
5.3 Lovaza
5.4 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Cardiovascular diseases
6.3 Diabetes
6.4 Neurological disorders
6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca plc
9.2 Amarin Corporation plc
9.3 Camber Pharmaceuticals, Inc.
9.4 Dr. Reddy’s Laboratories Ltd.
9.5 GSK plc
9.6 Grupo Ferrer Internacional, S.A.
9.7 Hikma Pharmaceuticals PLC
9.8 Natco Pharma Limited
9.9 Pfizer Inc.
9.10 Viatris Inc.
9.11 Zydus Lifesciences Limited
